Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design.
Maitland M, Ou S, Tolcher A, LoRusso P, Bahceci E, Ball H, Park J, Yuen G, Pesco Koplowitz L, Li T. Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design. Journal Of Clinical Oncology 2014, 32: 2624-2624. DOI: 10.1200/jco.2014.32.15_suppl.2624.Peer-Reviewed Original ResearchOral anaplastic lymphoma kinase (ALK) inhibitorPhase 1 trial designsAnaplastic lymphoma kinase inhibitorsTrial designKinase inhibitors